Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand name Yurpeak in India. This move aims to expand drug availability beyond cities,

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here are three things beyond the headline numbers that investors should know before trying to evaluate the company's recent performance.

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the company received the green light to bring in the KwikPen version, a pre-filled injection pen that allows easier administration,